Cargando…
Case report: the dissociated response and clinical benefit of primary leiomyosarcoma of the bone treated with penpulimab plus lenvatinib after failed multi-line therapy
Leiomyosarcoma occurring in the bone as primary tumor localization is extremely scarce with limited cases described in the literature, accounting for less than 0.7% of all primary bone malignancies. Once distant metastasis occurs, patients have limited treatments and often a somber prognosis, which...
Autores principales: | Wang, Bin, Han, Yin, Liu, Jie, Zhang, Xinyao, Zhuo, Hongyu, Jiang, Yu, Deng, Yaotiao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665504/ https://www.ncbi.nlm.nih.gov/pubmed/38026935 http://dx.doi.org/10.3389/fphar.2023.1239699 |
Ejemplares similares
-
Comprehensive Treatment of Trans-Arterial Chemoembolization Plus Lenvatinib Followed by Camrelizumab for Advanced Hepatocellular Carcinoma Patients
por: Liu, Juanfang, et al.
Publicado: (2021) -
A case of pembrolizumab and lenvatinib as an alterntive therapy for leiomyosarcoma
por: Mehta, Naaman, et al.
Publicado: (2023) -
Cost-effectiveness analysis of transarterial chemoembolization combined with lenvatinib as the first-line treatment for advanced hepatocellular carcinoma
por: He, Ying, et al.
Publicado: (2023) -
Penpulimab-induced complete atrioventricular block in a patient with metastatic renal cancer
por: Shen, Lishui, et al.
Publicado: (2023) -
Lenvatinib resistance mechanism and potential ways to conquer
por: Bo, Wentao, et al.
Publicado: (2023)